Tempest Therapeutics Inc (TPST) Stock Analysis
Verdict: AVOID
Severe cash burn leaves under 4 months of runway, forcing imminent dilution despite pipeline momentum from the Senlang CAR-T deal.
Investment score: 30/100
Analysis as of
Is Tempest Therapeutics Inc stock worth reviewing? AI model thesis
The AI model views TPST as a high-risk pre-revenue biotech where immediate dilution risk offsets pipeline momentum. Despite a 60.18% catalyst-driven move on a CD7 CAR-T agreement, cash runway of ~3.4 months poses severe existential downside for equity holders.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Tempest Therapeutics Inc opportunities and risks
What speaks for TPST
- In Vivo CAR-T Pipeline Expansion via Senlang Deal
What speaks against TPST
- Imminent Equity Dilution Risk (<4 Months Runway)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| TPST | n/a | 0.0x | n/a | 0.0% | 0.0% | -107.2% |
| LGVN | n/a | 17.1x | n/a | 69.8% | -1977.6% | -101.6% |
| GRDX | n/a | 61.6x | n/a | -1532.5% | -12789.6% | -82.2% |
| AIXC | n/a | 0.0x | n/a | 0.0% | 0.0% | -62.8% |
| NEUP | n/a | n/a | n/a | 104.7% | 272.0% | 294.2% |
| JSPR | n/a | 0.0x | n/a | 0.0% | 0.0% | -639.0% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -82.2% |
Frequently asked questions about Tempest Therapeutics Inc (TPST)
Is TPST stock a good investment?
The cached TradeMates AI model rates Tempest Therapeutics Inc as AVOID with an investment score of 30/100. The AI model views TPST as a high-risk pre-revenue biotech where immediate dilution risk offsets pipeline momentum. Despite a 60.18% catalyst-driven move on a CD7 CAR-T agreement, cash runway of ~3.4 months poses severe existential downside for equity holders. This is algorithmic model output, not personal investment advice.
Is TPST stock a buy?
The TradeMates model verdict for TPST is AVOID with an investment score of 30/100. Treat this as a model signal to review, not a personal buy recommendation.